Suppr超能文献

Xp11.2 易位性肾细胞癌的临床病理特征和预后:多中心、倾向评分匹配分析。

Clinicopathologic Characteristics and Prognosis of Xp11.2 Translocation Renal Cell Carcinoma: Multicenter, Propensity Score Matching Analysis.

机构信息

Department of Urology, Dongtan Sacred Heart Hospital, Hwaseong, Korea.

Department of Urology, Seoul National University Hospital, Seoul, Korea.

出版信息

Clin Genitourin Cancer. 2017 Oct;15(5):e819-e825. doi: 10.1016/j.clgc.2017.04.015. Epub 2017 Apr 26.

Abstract

BACKGROUND

We evaluated the clinicopathologic characteristics and prognosis of Xp11.2 translocation (Xp11.2t) renal cell carcinoma (RCC) from a multicenter study and compare them with clear-cell RCC using a propensity score matching analysis.

PATIENTS AND METHODS

Between 2004 and 2013, 8384 consecutive patients from 7 institutions who were diagnosed with RCC were reviewed, and the pathologically confirmed Xp11.2t cases were enrolled. The oncological outcomes of Xp11.2t were compared with those of clear-cell RCC by selecting matched cases using 1:3 propensity score matching methods in a precollected clear-cell RCC data set from our hospital. The patients were divided into 2 subgroups on the basis of age of onset, either before (early) or after (late) 45 years old.

RESULTS

Xp11.2t was found in 61 cases, corresponding to 0.72% of RCC cases for the 10 years. The mean age was 38.2 ± 19.4 years, and the mean tumor size was 6.2 ± 3.9 cm. The Xp11.2t cases were at more advanced stages and showed tendencies to involve lymph nodes at diagnosis. After the matching, there were no significant differences in recurrence-free and overall survival compared with clear-cell RCC. The age of incidence for Xp11.2t had a bimodal distribution, which was most common in the 30s and smaller peak in the 60s. Xp11.2t corresponded to a significantly worse prognosis for overall survival in late onset (after 45 years) subgroup (P = .038; hazard ratio, 3.199; 95% confidence interval, 1.065-9.609).

CONCLUSION

This neoplasm has more aggressive clinicopathologic features at diagnosis. In older patients with onset age > 45 years, Xp11.2t showed a significantly worse prognosis than clear-cell RCC.

摘要

背景

我们从多中心研究中评估了 Xp11.2 易位(Xp11.2t)肾细胞癌(RCC)的临床病理特征和预后,并通过倾向评分匹配分析将其与透明细胞 RCC 进行了比较。

患者和方法

在 2004 年至 2013 年间,回顾了来自 7 家机构的 8384 例连续确诊的 RCC 患者,并纳入了经病理证实的 Xp11.2t 病例。通过使用我们医院预先收集的透明细胞 RCC 数据集的 1:3 倾向评分匹配方法选择匹配病例,比较 Xp11.2t 的肿瘤学结果与透明细胞 RCC 的肿瘤学结果。根据发病年龄,将患者分为 2 个亚组,即 45 岁前(早期)或 45 岁后(晚期)。

结果

Xp11.2t 见于 61 例,占 10 年期间 RCC 病例的 0.72%。平均年龄为 38.2 ± 19.4 岁,平均肿瘤大小为 6.2 ± 3.9 cm。Xp11.2t 病例在诊断时处于更晚期,并倾向于淋巴结受累。匹配后,与透明细胞 RCC 相比,无复发生存率和总生存率无显著差异。Xp11.2t 的发病年龄呈双峰分布,最常见于 30 多岁,60 多岁时有较小的高峰。Xp11.2t 与发病年龄较大(>45 岁)亚组的总生存预后显著更差相关(P =.038;风险比,3.199;95%置信区间,1.065-9.609)。

结论

这种肿瘤在诊断时具有更具侵袭性的临床病理特征。对于发病年龄>45 岁的老年患者,Xp11.2t 的预后明显比透明细胞 RCC 差。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验